Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019

Fahad Aziz, Didier Mandelbrot, Tripti Singh, Sandesh Parajuli, Neetika Garg, Maha Mohamed, Brad C. Astor, and Arjang Djamali

ABSTRACT

Background. Kidney transplant recipients (KTR) present unique characteristics, including disease vintage, immunosuppression, and single functioning kidneys. We conducted preliminary analyses to assess the impact of coronavirus disease 2019 (COVID-19) on outcomes in KTR compared to nontransplant patients.

Methods. We evaluated published information in peer-reviewed journals between January 1, 2020, and April 24, 2020, with available data on acute kidney injury (AKI), renal replacement therapy (RRT), intensive care unit (ICU) stay, and death and compared clinical outcomes in KTR vs nontransplant recipients with COVID-19.

Results. A total of 19 published articles were identified, including a total of 88 KTR and 5342 nontransplant patients. The sample size varied between 2 and 2634. Mean age was 58.6 years vs 58.9 years in KTR vs nontransplant patients. Patient-level incidence of AKI (27.5% vs 13.3%, \( P < .001 \)), RRT (15.4% vs 3.3%, \( P < .001 \)), ICU stay (34.1% vs 15.1%, \( P < .001 \)), and death (22.7% vs 16.2%, \( P = .10 \)) was higher in KTR, representing relative risks of 2.06 (1.44, 2.96), 4.72 (2.62, 8.51), 2.25 (1.67, 3.03), and 1.41 (0.95, 2.08), respectively.

Conclusion. Early results suggest that the KTR are at significantly higher risk of AKI, RRT, and ICU stay from SARS-CoV-19 infection compared to the general population. The risk of death may not be significantly different.
an impact factor > 2.5 between January 1, 2020, and April 24, 2020. Single case reports were not included. We compared these clinical outcomes in patients with and without kidney transplantation using patient-level analyses. Studies of autopsies were excluded from mortality analyses.

RESULTS

We identified 19 case series [1–19], 6 of which included only KTR (Table 1) [12–15,17,19]. A total of 5342 patients with SARS-CoV-19 infection were included in the studies of nontransplant patients, and a total of 88 were included in the studies of KTR. The sample size varied between 2 and 2634 patients (Table 1). The mean age was 58.6 years vs 58.9 years in KTR vs nontransplant patients. Patient-level incidence of AKI (27.5% vs 13.3%, P < .001), RRT (15.4% vs 3.3%, P < .001), ICU stay (34.1% vs 15.1%, P < .001), and death (22.7% vs 16.2%, P = .10) was higher in KTR (Table 2, Fig 1), representing relative risks of 2.06 (1.44, 2.96), 4.72 (2.62, 8.51), 2.25 (1.67, 3.03), and 1.41 (0.95, 2.08), respectively (Table 2). Mean age was not statistically associated with the prevalence of death, ICU admission, or need for renal replacement therapy (P value = .1) in analyses weighted by the relative size of each study.

DISCUSSION

With the sudden and unexpected spread of COVID-19 throughout the world, there is significant uncertainty about the management of patients with the virus. This uncertainty becomes further complicated when KTR, a particularly vulnerable group, are infected with SARS-CoV-19. We analyzed the recent literature and compared outcomes between KTR and the general population. Our analysis indicated that AKI, RRT, ICU stay, and death were more common in KTR with COVID-19. Although the difference in mortality did not reach statistical difference, the other outcomes were significantly worse in KTR.

Not all published data reported poor outcomes in KTR. In a recent case series from Columbia University in New York, KTR with SARS-CoV-19 infection were found to have a similar presentation and favorable outcomes compared to the general population [17]. On the other hand, Akalin et al [19] observed high rates of AKI, need for RRT, and death in KTR, which is intriguing because both studies reported data from NYC. However, similar to the Akalin study, others have found rapid disease progression

### Table 1. Summary of Studies and Clinical Outcomes

| First Author | Journal                  | Transplant | N | Age | AKI | RRT | ICU | Death | Reference |
|--------------|--------------------------|------------|---|-----|-----|-----|-----|-------|-----------|
| Yang         | Lancet Respir Med        | -          | 52| 59.7| 29.0%| 17.0%| 100.0%| 61.5%  | 1         |
| Zhou         | Lancet                  | -          | 191| 56  | 5.0% | 15.0%| 26.0%| 28.0%  | 2         |
| Chen         | BMJ                     | -          | 113| 68  | 25.0%| 2.6% | 82.0%| 100.0% | 3         |
| Chen         | Lancet                  | -          | 99 | 55.5| 9.0% | 9.0% | 4.0% | 11.0%  | 4         |
| Huang        | Lancet                  | -          | 41 | 49  | 7.0% | 7.0% | 31.0%| 15.0%  | 5         |
| Grein        | N Engl J Med            | -          | 53 | 64  | 6.0% | 0.0% | 64.0%| 13.0%  | 6         |
| Cheng        | Kidney Int              | -          | 701| 63  | 5.1% | 2.0% | 10.4%| 16.1%  | 7         |
| Gao          | N Engl J Med            | -          | 199| 58  | 4.5% | 4.5% | 22.0%| 22.0%  | 8         |
| Guan         | N Engl J Med            | -          | 1099| 47 | 0.5% | 0.8% | 5.0% | 1.4%   | 9         |
| Young        | JAMA                    | -          | 18 | 47  | 0.0% | 0.0% | 11.0%| 0.0%   | 10        |
| Wang         | Am J Nephrol            | -          | 116| 54  | 0.0% | 0.0% | 9.4% | 6.0%   | 11        |
| Richardson   | JAMA                    | -          | 2634| 63 | 22.2%| 3.2% | 14.2%| 21.0%  | 18        |
| Su           | Kidney Int              | -          | 26 | 69  | 35.0%| 19.0%| NA   | 100.0% | 16        |
| Banerjee     | Kidney Int              | +          | 7  | 54  | 42.0%| 42.0%| 60.0%| 14.0%  | 14        |
| Alberici     | Kidney Int              | +          | 20 | 59  | 30.0%| 5.0% | 20.0%| 25.0%  | 15        |
| Akalin       | N Engl J Med            | +          | 36 | 60  | 16.0%| 16.0%| 27.0%| 28.0%  | 19        |
| Gandolfini   | Am J Transplant         | +          | 2  | 63  | 50.0%| 0.0% | 0.0% | 50.0%  | 12        |
| Fernandez-Ruiz| Am J Transplant       | +          | 8  | 69  | NA   | NA   | NA   | 75.0%  | 13        |
| Columbia Univ.| JASN                   | +          | 15 | 51  | 40.0%| NA   | NA   | 27.0%  | 17        |

Abbreviations: AKI, acute kidney injury; ICU, intensive care unit; RRT, renal replacement therapy.
and poor outcomes in KTR [12–15]. While environmental and social-economic factors might, in part, explain the differences in these observations, KTRs have unique characteristics including immunosuppression, single functioning kidneys, and potentially long disease vintage that place them at a higher risk of progression and death with COVID-19.

It is not clear how immunosuppression should be managed after the diagnosis of SARS-CoV-19 infection in KTR. Current recommendations are based on expert opinions only. Most centers prefer reducing the immunosuppression in KTR when diagnosed with COVID-19; however, the specifics remain unknown. While it seems logical to avoid T-cell depletion for induction therapy in pandemic areas, it is unclear how immunosuppression management can prevent or mitigate the cytokine storm, known to be associated with poor outcomes in patients with COVID-19. Furthermore, despite the favorable outcomes of high-dose dexamethasone treatment for acute respiratory distress syndrome [20], the role of intravenous steroids in KTR with COVID-19 remains unknown.

We recognize several limitations to our study, including the lack of detailed characteristics of patients from each study, missing data from some studies, potential selection bias, and relatively few transplant recipients. Due to a lack of patient-level information, meta-analysis cannot be performed. Despite its limitations, our study highlights the importance of close follow-up in transplant recipients with SARS-CoV-19 treatment for acute respiratory distress syndrome [20], the role of intravenous steroids in KTR with COVID-19 remains unknown.

REFERENCES

[1] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–81.

[2] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.

[3] Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091.

[4] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.

[5] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

[6] Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med 2020;382:2327–36.

[7] Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97:829–38.

[8] Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382:1787–99.

[9] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.

[10] Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323:1488–94.

[11] Wang L, Li X, Chen H, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol 2020;51:343–8.

[12] Gandolfini I, Delsante M, Fiaccadori E, et al. COVID-19 in kidney transplant recipients. Am J Transplant 2020;20:1849–58.

[13] Fernandez-Ruiz M, Andres A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant 2020;20:1849–58.

[14] Banerjee D, Popoola J, Shah S, Ster JC, Quan V, Phamish M. COVID-19 infection in kidney transplant recipients. Kidney Int 2020;97:1076–82.

[15] Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int 2020;97:1083–8.

[16] Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 2020;98:219–27.
[17] Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York. 31. 6th ed. JASN; 2020. p. 1150–6.

[18] Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323:2052–9.

[19] Akalin EAY, Bartash R, Seethamraju H, et al. COVID-19 and kidney transplantation. NEJM 2020;382:2475–7.

[20] Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020;8:267–76.